Telix’s US$1.65 Billion ITM Deal Adds 105.8 Million Shares as Stock Falls 3%
Telix Pharmaceuticals has agreed to acquire ITM for US$1.65 billion, a move that will significantly expand its therapeutic pipeline and isotope supply chain. The deal involves a mix of equity and debt, causing Telix's stock to fall 3% as investors weigh the dilution of shares against the strategic benefits.
Why it matters
This acquisition represents a major consolidation in the radiopharmaceutical sector, impacting both market competition and the availability of critical medical isotopes.
Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX) fell 3.03% to A$17.31 in Sydney. The move followed its agreement to buy private ITM for US$1.65 billion upfront.
The deal would issue 105.8 million Telix shares. ITM sellers would own 23.7% of the enlarged company after closing.
That dilution is the immediate investor cost. The offset is control of a profitable isotope supplier with US$273 million of 2025 revenue.
Sources: Google Finance and Telix . As of September 21, 2026, 10:02 AEST. Units: Australian dollars, shares and percent. Comparisons are TS2 calculations from reported data.
The opening auction produced 343,590 shares of volume. That equalled 16.2% of Telix’s average daily volume within two minutes.
The stock remained 4.0% above the A$16.65 deal-pricing reference. Sellers therefore had not gained an immediate paper discount.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in